KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Equity: 2021-2025

Historic Return on Equity for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to -0.73%.

  • Recursion Pharmaceuticals' Return on Equity fell 5.00% to -0.73% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.73%, marking a year-over-year decrease of 5.00%. This contributed to the annual value of -0.62% for FY2024, which is 7.00% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Return on Equity stood at -0.73% for Q3 2025, which was down 3.90% from -0.70% recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Return on Equity ranged from a high of 0.44% in Q1 2021 and a low of -0.82% during Q1 2024.
  • Over the past 3 years, Recursion Pharmaceuticals' median Return on Equity value was -0.68% (recorded in 2024), while the average stood at -0.67%.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Return on Equity crashed by 84bps in 2022, and later climbed by 24bps in 2025.
  • Recursion Pharmaceuticals' Return on Equity (Quarterly) stood at -0.32% in 2021, then fell by 24bps to -0.56% in 2022, then decreased by 17bps to -0.73% in 2023, then grew by 13bps to -0.59% in 2024, then declined by 5bps to -0.73% in 2025.
  • Its last three reported values are -0.73% in Q3 2025, -0.70% for Q2 2025, and -0.58% during Q1 2025.